NEW YORK (GenomeWeb) – Agendia said Tuesday that updated guidelines from the European Group on Tumor Markers named the firm's MammaPrint 70-gene signature test "as the first and currently the only multigene test of its kind deemed to have level 1A evidence for its clinical use."
To read the full story....
Register for Free....and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.